Rocket Lab appoints Dr. Edward Frank to Board of Directors, expanding to nine members

Rocket Lab Corp

Board increased from eight to nine directors; Dr. Frank appointed as Class II director with term expiring at 2023 annual meeting.
Dr. Frank brings 35+ years of tech leadership, including roles at Apple (VP, Mac Hardware), Broadcom (R&D VP), and founding CEO of Epigram.
Standard non-employee director compensation: initial $360K RSU grant vesting over 3 years and annual $180K RSU grant.
Dr. Frank qualifies as an independent director under Nasdaq rules; company will enter indemnification agreement.
No transactions exceeding $120K between Dr. Frank and company; no arrangements for his appointment other than standard terms.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Dr. Edward H. Frank

Class II Director

RKLB · Rocket Lab Corp

Effective: 2022-09-02
Filed: September 6, 2022, 7:59 PM ET

On September 2, 2022, the Board appointed Dr. Edward H. Frank as a Class II director to fill the newly-created vacancy on the Board, with an initial term expiring at the Company’s 2023 annual meeting of stockholders.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. Edward H. Frank was appointed as Class II Director at Rocket Lab Corp.

Action: appointed
Role: Class II Director

Exact text from the filing

On September 2, 2022, the Board appointed Dr. Edward H. Frank as a Class II director to fill the newly-created vacancy on the Board, with an initial term expiring at the Company’s 2023 annual meeting of stockholders.

View on SEC.gov

Rocket Lab Corp filing history →

Source: SEC EDGAR

accession 0000950170-22-018121

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.